A promising new Alzheimer’s drug could help spell “the beginning of the end” for the neurodegenerative disease.

US pharmaceutical giant Eli Lilly will announce the full clinical trial results for its Alzheimer’s drug donanemab at a conference in Amsterdam today.

The drug, which is taken as a monthly infusion into the bloodstream for 18 months, was found to slow mental decline by 36% in phase 3 trials, the company announced in May.

It works by targeting and removing clusters of the protein amyloid in the brain.

“After 20 years with no new Alzheimer’s disease drugs in the UK, we now have two potential new drugs in 12 just months,” Dr Richard Oakley, associate director at the Alzheimer’s Society, wrote in The Mirror.

“This could be the beginning of the end for Alzheimer’s disease.”

It comes after trials showed another drug called lecanemab slowed progression of Alzheimer’s symptoms by 27% in patients in the early stages of the disease. The drug was approved for use in the US earlier this month.

Alzheimer’s: First drug to slow progression of disease gains approval of US regulator the FDA

Heart attacks increase risk of cognitive decline for years, study finds

Alzheimer’s: New drug can reduce disease symptoms by up to 35%

Be the first to get Breaking News

Install the Sky News app for free

After the results of the donanemab trial are released, experts around the world will study the findings to examine the benefits of the drug and whether they outweigh the risk of side effects.

Such risk factors could include brain swelling and bleeding.

Regulators in the UK would need to assess the drug to decide whether to licence it as safe – a process that could take between 12 and 18 months – then the NHS would decide which patients it can be prescribed to based on cost-effectiveness.

Estimates suggest the drugs could help 720,000 people, according to the Alzheimer’s Society and Alzheimer’s Research UK, including 286,000 with mild Alzheimer’s and 435,000 with mild cognitive impairment, which is a precursor to the disease.

Is UK ready for new Alzheimer’s drugs?

However, doctors previously warned thousands of patients in the UK may miss out on the benefits if such drugs become available due to a lack of brain scanners and specialist clinics.

Amyloid plaques can be detected by taking a sample of spinal fluid or by a PET scan, of which there are around 86 scanners in the UK.

Click to subscribe to the Sky News Daily wherever you get your podcasts

Around 850,000 people in Britain have Alzheimer’s disease, which is the most common form of dementia.

It causes mild memory loss and can seriously affect a person’s ability to carry out ordinary daily activities.

Related posts:

Tesla Bots may be the latest in a long line of Elon Musk claims that haven’t come to fruition Giant ‘sea dragon’ skeleton is one of UK’s ‘greatest’ dinosaur-era finds, experts say Two new drugs to tackle superbugs that ‘will save many lives’ on verge of being available to NHS patients Google sued for using the NHS data of 1.6 million Brits ‘without their knowledge or consent’ Scientists develop tool to identify patients most at risk of COVID death Facebook users report seeing ‘random’ posts to celebrities in their feed Game changer? Europe’s biggest ever discovery of rare metals used to make phones and cars Search engine wars: Battle of the chatbots Major genetics breakthrough could herald new era of tests and treatments Google unveils its first folding phone – with an eye-watering price tag AI’s rapid revolution – can we keep up? University’s data ‘likely copied’ in cyberattack